Voyager Acquisition Corp. (VACH)

NASDAQ: VACH · Real-Time Price · USD
10.48
0.00 (0.00%)
Oct 23, 2025, 4:00 PM EDT - Market closed
Market Cap331.43M
Revenue (ttm)n/a
Net Income (ttm)9.17M
Shares Out 31.63M
EPS (ttm)0.31
PE Ratio33.38
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,667
Open10.48
Previous Close10.48
Day's Range10.48 - 10.48
52-Week Range10.01 - 11.20
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About VACH

Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. The company was incorporated in 2023 and is based in Brooklyn, New York. [Read more]

Sector Financials
IPO Date Aug 9, 2024
Country United States
Stock Exchange NASDAQ
Ticker Symbol VACH
Full Company Profile

Financial Performance

Financial Statements

News

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

Partnership combines Secarna's OligoCreator® platform with VERAXA's technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases Partnership combines Secarna'...

23 days ago - GlobeNewsWire

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempt...

3 months ago - GlobeNewsWire

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with...

5 months ago - GlobeNewsWire

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel...

5 months ago - GlobeNewsWire